Literature DB >> 3494569

Cardiovascular effects and safety of intravenous and intramuscular pentamidine isethionate.

D L Mallory, J E Parrillo, K R Bailey, G L Akin, M Brenner, H C Lane, A S Fauci, H Masur.   

Abstract

Intramuscular (im) pentamidine isethionate can cause substantial local pain and inflammation at the injection site. This drug is being used more frequently in recent years to treat Pneumocystis pneumonia, particularly in patients with acquired immunodeficiency syndrome. Clinicians began administering it iv despite warnings that iv administration might cause severe hypotension. We investigated the safety of im and iv pentamidine, monitoring hemodynamics after each dose in 11 patients with intra-arterial lines. Results showed only a small (but statistically significant) fall in mean arterial pressure after both im and slow (60 min) iv administration. A concomitant decrease in pulse occurred, but no change in cardiac output, pulmonary capillary occlusion pressure or systemic vascular resistance was noted. These results suggest that it may be safe to infuse pentamidine slowly intravenously. This route is more comfortable to patients than im administration.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3494569     DOI: 10.1097/00003246-198705000-00010

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  3 in total

1.  Torsades de pointes during intravenous pentamidine isethionate therapy.

Authors:  P Mitchell; P Dodek; L Lawson; M Kiess; J Russell
Journal:  CMAJ       Date:  1989-01-15       Impact factor: 8.262

Review 2.  Pentamidine. A risk-benefit analysis.

Authors:  B Wispelwey; R Pearson
Journal:  Drug Saf       Date:  1990 May-Jun       Impact factor: 5.606

Review 3.  Treatment and prophylaxis of Pneumocystis carinii pneumonia in AIDS patients.

Authors:  D Smith; B Gazzard
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.